How Primary Health Care rolled up Australian pathology, imaging and medical centres, and why a decade of deals left shareholders below their 1998 IPO price.
Healius Limited (ASX: HLS), formerly Primary Health Care (ASX: PRY), is an Australian healthcare company spanning pathology, diagnostic imaging and medical centres. It grew into one of the country's largest diagnostic providers, processing about one in four Medicare-funded pathology tests.
The company grew by acquisition. It bought pathology labs, imaging businesses and a major listed competitor (Symbion Health, ~$2.65bn).
Today Healius is a near pure-play pathology business. It sold its medical centres to BGH Capital in 2020 ($500m) and Lumus Imaging to Affinity in 2025 ($965m), and is running a turnaround plan (T27) to lift thin pathology margins by 2027.
An investor at the 1998 IPO (~$1.00) saw the stock peak near $9.44 in February 2008 and trade below $0.70 in early 2026. Dividends over the years and the 41.3 cent special dividend in 2025 offset only part of the capital loss.
Primary Health Care was founded by Dr Edmund (Ed) Bateman, a Sydney GP. He opened his first large-scale bulk-billing medical centre at Brookvale in 1985 and led the company from its 1998 float until his retirement in 2014.
Bateman built a distinct model: pay GPs a lump sum of around $500,000 for a five-year exclusive contract, keep the patient records, and direct pathology and imaging referrals to Primary's own labs. The model drove growth but also doctor disputes, culture problems and long-running tax litigation.
The company listed on the ASX in 1998 with a market value of about $90m; Bateman held roughly 21–25%. At its diversified peak it ran dozens of large medical centres, thousands of collection centres and scores of imaging sites. In 2025, as a pathology pure-play, it operated:
Healius earns most of its revenue from diagnostic volume funded by Medicare. Doctors refer patients for tests; the company collects samples, processes them in its labs, and bills through the Medicare Benefits Schedule.
Pathology is a scale game. The marginal cost of one more test is low, so volume drives margin. Acquisitions added test volume, geographic coverage and lab utilisation.
The old medical centres (prior to the 2020 sale) earned bulk-billing fees and service fees from doctors, and generated the pathology and imaging referrals that fed the group's own labs and imaging sites. The core logic was vertical referral capture. By owning the medical centres and contracting the doctors, Primary controlled the referral flow into its own pathology and imaging businesses.
The strategy ran on two tracks. The first was the doctor "acquisition" model. Primary paid individual GPs a large upfront lump sum (commonly around $500,000) for a five-year exclusive contract to practise from a Primary centre. The company kept the patient lists, records and equipment. In substance, Primary was buying a five-year income stream and the referral flow attached to it.
Almost all of Healius's pathology and imaging scale came through acquisition, and the logic in both was the same: buy referral flow and network density. Below the corporate deals, the 2010 deregulation of collection centre licences shifted the race to sites. Each centre is small, but density decides market share, and a lab is a fixed-cost machine where every acquired referral stream drops mostly to gross margin. Imaging followed the same referral logic but, being more capital-hungry, grew mainly through sites attached to the medical centres plus selective bolt-ons rather than a roll-up.
Entry multiples were rarely disclosed. Symbion was pitched on synergies of $95–105m a year, not a multiple. Agilex was struck at ~19–21× EBITDA and ~8× revenue. The clearest multiples came on exit: 13× earnings for the medical centres, 17× EBITDA for Lumus Imaging.
Targets had to add diagnostic volume, geographic footprint or a growth adjacency, with synergies through shared labs, collection networks and back office. Primary bought pathology assets in underrepresented states, then adjacencies: day hospitals, IVF and clinical-trials bioanalysis.
Deals came from deep industry knowledge and the company's position as an established consolidator, supported by investment banks. Symbion was tracked for years; Bateman said Primary had considered buying its assets for more than five years before turning hostile in 2007.
The company completed dozens of transactions: many small doctor and collection-centre deals, a handful of large corporate acquisitions, and in the last five years large divestments. The pattern: debt-funded expansion peaking with the ~$2.65bn Symbion takeover in 2008, a decade of digestion, then a full reversal into a pathology pure-play after Bateman passed away. Since 2020 the group has sold nearly $1.5bn of assets and returned capital.
Listed on the ASX in 1998 at a market value of ~$90m. Steady roll-up of medical centres, collection sites and doctor lump-sum contracts. $158m of lump-sum payments made to 505 practitioners across 18 new centres.
Hostile takeover at $4.10 cash per share. Built a 20% blocking stake; unconditional at 54% in February 2008. On-sold Symbion Consumer to Sanofi ($560m) and Pharmacy to Zuellig ($505m) to cut debt.
Bought Healthscope's Queensland pathology assets (the ACCC later forced divestiture of 70+ collection centres) and the small insurer Transport Health. Full acquisitions.
Acquired Montserrat Day Hospitals for up to ~$138.5m, funded by a $250.5m raise. Renamed Healius in December 2018. Rejected Jangho's $3.25/share (~$2bn) proposal in January 2019 as opportunistic.
Sold the medical centres business to BGH Capital for $500m, about 13× FY19 earnings of $37.5m. The referral-capture business model was over and the pure lab play began to take shape.
All-cash, debt-funded acquisition of Australia's largest bioanalytical lab at ~19–21× EBITDA (~8× revenue), plus Axis Diagnostics (~$12.6m). Sold Adora Fertility and day hospitals 2022–23.
Australian Clinical Labs offered 0.74 of its shares per Healius share (~$1.58bn). The board rejected it and the ACCC opposed it, as the pair would control over half of Australia's collection centres. ACL withdrew.
Sold Lumus Imaging to Affinity Equity Partners at a $965m enterprise value: 17.0× FY24 EBITDA, 25.4× EBIT. Debt repaid in full.
Primary listed around $1.00 in 1998 and rose strongly through the 2000s, peaking at about $9.44 in February 2008, the exact month the Symbion takeover went unconditional. The stock then roughly halved within months as debt and the GFC bit, and never recovered. It traded in the $3–5 range through the 2010s, spiked to ~$4.63 in the COVID testing boom, then fell to ~$1.50 by mid-2024 and below $0.70 by early 2026, near all-time lows.
Chart (bubbles): Healius share price at key points
Source: Deal Advisory analysis. Early 2026 shown at $0.70; the shares traded below that level.
On balance, acquisitions hindered the share price more than they helped. Symbion was struck at the top of the market with expensive debt and dilutive equity, and marked the all-time high. The later diagnostics roll-up added goodwill that was subsequently written off. The one period of strong earnings, COVID, came from an external demand shock, not from acquisitions, and it reversed sharply.
The company as a whole was never acquired, despite several approaches. Jangho's January 2019 proposal at $3.25 a share (~$2bn) was rejected as opportunistic and undervaluing the company. In hindsight that rejection looks expensive; the shares have never traded near $3.25 since. The 2023 Australian Clinical Labs scrip merger (~$1.58bn) was rejected by the board, then opposed by the ACCC, and lapsed.
Value was instead realised in parts, at healthy multiples: the medical centres went to BGH Capital for $500m (~13× earnings) in 2020, and Lumus Imaging went to Affinity for a $965m enterprise value (17.0× FY24 EBITDA, 25.4× EBIT) in 2025.
The problem was never asset quality. It was that the market refused to value the conglomerate at anything like the sum of its parts.
Symbion was strategically defensible but financially reckless: bank debt plus a $1.23bn rights issue to buy a larger company just before the GFC. The deal marked the share price's all-time high.
Lesson: match deal size and leverage to what the balance sheet can survive through a down cycle in the market.
Paying doctors upfront captured referrals, but bred disputes, cultural damage and tax litigation. $158m of payments were ruled non-deductible capital by the ATO and Federal Court.
Lesson: a roll-up built on contracted individuals is more fragile than one built on owned, durable assets.
The group paid growth multiples (Agilex at ~20× EBITDA) and later wrote goodwill off: $349.8m in FY23 and $603.2m in FY24.
Lesson: paying for future, unrealised growth is risky.
Record COVID profits tempted a $200m buyback at peak prices. When PCR demand vanished, the cost base and debt remained, forcing a deeply discounted raise in 2023.
Lesson: treat boom earnings as temporary. Strengthen the balance sheet; don't buy back stock at the top.
It was one of those rare companies where the parts were worth more than the sum. The sale of the medical centre and imaging assets for 13× and 17× showed underlying value that wasn't reflected in the share price of the whole company.
Lesson: a diversified structure does not always make sense if the business is too complex and the synergies aren't evident.
The strategy built scale, strong brands and sellable assets, but the shares fell from $9.44 to under $0.70. Scale bought with debt at high multiples is not value.
Lesson: acquiring businesses at fair multiples and accounting for market cycles is key to a successful acquisition strategy.
Get a free, data-backed estimate of what your business could be worth.
Get your free appraisal
